Mutational profiling of lung adenocarcinoma in China detected by next-generation sequencing

• Published in: Journal of cancer research and clinical oncology Vol. 146; no. 9; pp. 2277 - 2287
• Main Authors: Zhou, Xiaoyun, Xu, Xiaohui, Tian, Zhenhuan, Xu, Wang-Yang, Cui, Yushang
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2020; Springer Nature B.V
• Subjects: Adenocarcinoma; Cancer Research; Decision making; Drug development; Epidermal growth factor receptors; ErbB-2 protein; Gender; Gene frequency; Hematology; Internal Medicine; Lung cancer; Medicine; Medicine & Public Health; Mutation; Next-generation sequencing; Non-small cell lung carcinoma; Oncology; Original Article – Cancer Research; p53 Protein; Patients; Pleura; Tumors; China; Mutations; NGS; Targeted therapy; LUAD
• ISSN: 0171-5216; 1432-1335
• DOI: 10.1007/s00432-020-03284-w

Purpose NSCLC is the most common type of lung cancers. The purpose of this study is to screen cancer-related mutations in early LUAD in China through NGS technology, determine their correlation with clinical characteristics and provide basis for treatment decisions. Methods In this study, we performed a 583 gene panel to detect the mutational spectrum of the tumors which were collected from 98 LUAD patients. The sequencing data and clinical characteristics were analyzed. Results Mutations were identified in 94.9% of patients. EGFR had the highest mutation frequency which was detected in 66% of the patients and was significantly associated with female gender and non-smoking history. Other genes with high mutation frequency were TP53 (37%), ERBB2 (24%), BCOR (22%), ZFHX3 (19%), BTG1 (17%), ATR (16%), WWTR1 (15%), etc. TP53 mutations were significantly associated with medium and low differentiation of tumors; BCOR and BLM mutations with gender; WWTR1 mutations with age; and ATR mutations with visceral pleura invasion were observed. 61% of the patients harbored at less one actionable alteration associated with FDA-recognized or investigational drugs. Conclusion Multiple mutations in LUAD patients in this study have not previously been reported in NSCLC. Moreover, mutations in driver genes including EGFR , TP53 , BCOR, BLM , WWTR1 , and ATR were significantly related to clinical features. The panel used in this study is an effective approach for molecular analysis and can be applied in personalized treatment decision-making and drug development.